Mineralocorticoid Receptor Antagonists (MRA) have proven their cardioprotective effects in individuals with chronic heart failure (CHF) by minimizing the cardiovascular damages caused by the excessive aldosterone production observed in those patients. Metabolic syndrome (MetS) that represents one of the major risk factors for CHF has been also reported to be associated with increased aldosterone levels and MR activation and may contribute in that way to the pathogenesis of HF. Thus, we hypothesized that targeting the MetS by the early antagonism of the MR may prevent or delay the subsequent transition to CHF in a rat model of HF associated or not with a MetS. MRA Eplerenone (100 mg/kg/day) or placebo was administrated to 1.5 month-old obese and lean Spontaneously Hypertensive Heart Failure male rats (SHHF cp/cp and SHHF +/+ respectively) for a period of 11 months. Animal metabolic and cardiac parameters were regularly monitored during the protocol. When compared to the SHHF +/+ , MetS rats induces of mortality of 30% in SHHF cp/cp group that was completely prevented by the preventive treatment with Eplerenone. Indeed, SHHF cp/cp developed over time a massive obesity, dyslipidemia and insulin resistance. Echocardiograms showed an accelerated transition to cardiac dysfunction evidenced by left ventricular hypertrophy (LVH), a decreased relaxation and contractile properties of the myocardium as well as LV dilatation. MRA, prevented rats' body weight gain (-10%), dyslipidemia (-50%) and enhanced adiponectinemia (+50%). Independently of a blood pressure decrease, cardiac parameters of Eple-SHHF cp/cp rats were preserved compared to SHHF cp/cp : LV diameter (9.9±0.14 vs 11.4±0.13 mm, respectively), LV mass (1760±72 vs 2195±73 mg), ejection fraction (70±1 vs 59±1%), isovolumic relaxation time (30±1 vs 22±1 ms) and E/A ratio (1.7±0.1 vs 3±0.3). Altogether, our data demonstrated that administration of eplerenone at the very early stages of MetS delayed their progression to CHF and prevented mortality. The beneficial cardioprotective effects were obtained via a mechanism independent of blood pressure lowering.
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Objective: We hypothesized that AMPK plays a crucial role in the control of MSC proliferation.
Methods: MSCs isolated from WT or AMPKα1 KO adult mouse bone marrow were stimulated with the specific AMPK activator, A769662. Protein phosphorylation state was determined by immunoblotting, cell viability was quantified by FACS after AnnexinV and Propidium Iodide staining, cell proliferation was quantified by EdU incorporation and gene expression was analyzed by real-time PCR.
Results: MSCs isolated from murine bone marrow exclusively expressed the AMPKa1 catalytic subunit. A769662 was able to induce a robust and sustained AMPK activation in WT MSCs but not in AMPKa1 KO MSCs. This A769662-dependent AMPK activation blocks WT MSC proliferation but not in KO MSCs without affecting their viability. Moreover, AMPKa1 deletion induces an increase of basal MSC proliferation. Among AMPK downstream targets proposed to regulate cell proliferation, we showed that neither the p70 ribosomal S6 protein kinase/eukaryotic elongation factor 2-dependent protein synthesis pathway nor p21 was involved, whereas p27 expression was increased by A-769662. Silencing p27 expression prevented the A-769662-dependent inhibition of MSC proliferation.
Conclusions:
These results suggest that activating AMPK promotes a principal prerequisite for cell differentiation, the arrest of MSC proliferation via p27 regulation. Cardiac failure is the most common cause of mortality in Friedreich ataxia (FRDA), a mitochondrial disease with neurodegeneration, hypertrophic cardiomyopathy and diabetes. FRDA is caused by reduced levels of frataxin (FXN), an essential mitochondrial protein involved in mitochondrial bioenergetics. To date, no treatment exists for FRDA cardiomyopathy. Here, we show that adenoassociated virus (AAV) rh10 vector expressing human FXN injected intravenously not only prevented the onset of the cardiac disease in a faithful FRDA cardiac mouse model, but also, when administered at the time of heart failure, reversed rapidly and completely cardiac disease at the functional, cellular and molecular level in all treated animals. Our results also demonstrate the capacity of defective cardiomyocytes with severe energy failure and ultrastructure disorganization to be rapidly corrected and remodeled by gene therapy. These results establish the primary proof-of-concept for developing gene therapy of FRDA cardiomyopathy. 
